Literature summary for 3.1.6.12 extracted from

Harmatz, P.; Yu, Z.F.; Giugliani, R.; Schwartz, I.V.; Guffon, N.; Teles, E.L.; Miranda, M.C.; Wraith, J.E.; Beck, M.; Arash, L.; Scarpa, M.; Ketteridge, D.; Hopwood, J.J.; Plecko, B.; Steiner, R.; Whitley, C.B.; Kaplan, P.; Swiedler, S.J.; Hardy, K.; Berger, K.I.; Decker, C.
Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase (2010), J. Inherit. Metab. Dis., 33, 51-60.

Application

Application	Comment	Organism
medicine	usage of ASB for enzyme replacement therapy in mucopolysaccharidosis type VI, overview	Homo sapiens

Localization	Comment	Organism	GeneOntology No.	Textmining
lysosome	-	Homo sapiens	5764	-

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue	Comment	Organism	Textmining

Synonyms	Comment	Organism
arylsulfatase B	-	Homo sapiens
ASB	-	Homo sapiens
N-acetylgalactosamine 4-sulfatase	-	Homo sapiens

General Information	Comment	Organism
malfunction	mucopolysaccharidosis type VI, i.e. MPS VI or Maroteaux-Lamy syndrome, is a lysosomal storage disease in which deficient activity of the enzyme N-acetylgalactosamine 4-sulfatase impairs the stepwise degradation of the glycosaminoglycan dermatan sulfate	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)